Toray Industries has entered into a licensing-agreement collaboration with Bonac on nucleic-acid candidate BNC-1021. Under the agreement, Toray gains exclusive rights in Japan to develop, market, and manufacture (not including the bulk drug substance) idiopathic pulmonary-fibrosis candidate BNC-1021.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
804.2 JPY | +6.24% |
|
+5.28% | +9.70% |
27/05 | Toray Industries to Build Advanced Materials Production Plant in South Korea's Gumi City | MT |
22/05 | Immunis Partners with Toray to Reverse Sarcopenia | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.70% | 764.54Cr | |
+1.62% | 10TCr | |
-6.47% | 6.25TCr | |
+87.14% | 5.25TCr | |
+6.44% | 3.53TCr | |
+2.82% | 3.18TCr | |
+6.73% | 1.92TCr | |
+18.21% | 1.76TCr | |
+8.81% | 1.39TCr | |
+75.12% | 1.28TCr |
- Stock Market
- Equities
- 3402 Stock
- News Toray Industries, Inc.
- Toray Enters into Licensing Agreement with Bonac on Nucleic Medicine Targeting Idiopathic Pulmonary Fibrosis